|
 |
Nekomercijalni |
|
|
Zaštićeni nazivi su indikativni i sastav ekscipijensa može biti različit ovisno o državi i laboratorijima
|
|
Mabthera |
Argentina, Australija, Austrija, Belgija, Čile, Danska, Egipat, Ekvador, Finska, Francuska, Grčka, Hrvatska, Irska, Island, Italija, Japan, Kolumbija, Luksemburg, Madžarska, Maroko, Meksiko, Nizozemska, Njemačka, Norveška, Novi Zeland, Peru, Poljska, Portugal, Rumunjska, Saudijska Arabija, Španjolska, Švedska, Švicarska, Tunis, Turska, Ujedinjeni Arapski Emirati, Velika Britanija, Venecuela |
|
Novex |
Argentina |
|
Reditux |
Čile, Peru |
|
Rigetuxer |
Meksiko |
|
Rituxan |
Japan, Kanada, S A D |
|
Rituximab |
Novi Zeland |
|
Rixathon |
Belgija, Francuska, Njemačka, Španjolska, Švicarska, Velika Britanija |
|
Truxima |
Belgija, Francuska, Kanada, Njemačka, S A D, Španjolska, Velika Britanija |
|
|
 |
 |
Bibliografija : Rituximab |
|
|
Vrsta |
Publikacija |
| 2296 |
Laboratorija |
Témocilline (Negaban®) - Résumé des caractéristiques du produit
Eumedica 2017 |
| 2825 |
Časopis |
Mueller C, Dietel E, Heynen S, Nalenz H, Goldbach P, Mahler H, Schmidt J, Grauschopf U, Schoenhammer K.
Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials.
Int J Pharm Compound 2015 ; 19, 3: 261-267. |
| 2881 |
Plakat |
Jaccoulet E, Guirao S, Morand K, Astier A, Paul M.
Stabilité d'un anticorps monoclonal d'intérêt thérapeutique après reconstitution: le rituximab.
SFPO Congress 2009 |
| 3323 |
Časopis |
Paul M, Vieillard V, Jaccoulet E, Astier A.
Long-term stability of diluted solutions of the monoclonal antibody rituximab.
Int J Pharm 2012 ; 436, 1-2: 282-290. |
| 4016 |
Časopis |
Vieillard V, Paul M, Ibrahim T, Astier A.
Extended stability of the rituximab biosimilar CT-P10 in its opened vials and after dilution and storage in polyolefin bag.
Ann Pharm Fr 2017 ; 75, 6: 420-435. |
| 4040 |
Časopis |
Lamanna W.C, Heller K, Schneider D, Guerrasio R, Hampl V, Fritsch C, Schiestl M.
The in-use stability of the rituximab biosimilar Rixathon®/Riximyo® upon preparation for intravenous infusion.
J Oncol Pharm Practice 2017 ;25,2: 269-278 |
| 4676 |
Plakat |
Borišek R, Šmid I.
Assessing the stability of Sandoz rituximab biosimilar after exposure to out-of-fridge conditions for 21 days.
EAHP Congress Vienna 2022 |
| 4708 |
Časopis |
Borišek R, Mischo A, Šmid I.
Study of the Stability of Sandoz Rituximab Biosimilar Rixathon®/Riximyo® When Subjected for up to 21 Days to Ambient Storage.
Drugs R D 2022 ; 22,3: 225–234 |
| 4740 |
Laboratorija |
MabThera 500 mg concentrate for solution for infusion. Summary of Product Characteristics Updated 07-Oct-2021
Roche Products Limited 2021 |
|
|
